Search
                    Epilepsy Paid Clinical Trials in Arizona
A listing of 14  Epilepsy  clinical trials  in Arizona  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 14
        
                The state of Arizona currently has 14 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa. 
            
                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/20/2025
            
            Locations: Xenoscience, Inc., Phoenix, Arizona  +1 locations         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/19/2025
            
            Locations: Barrow Neurological Institute, Phoenix, Arizona  +2 locations         
        
        
            Conditions: Generalized Epilepsy
        
            
        
    
                
                                    AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
                                
            
            
        Recruiting
                            
            
                The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/24/2025
            
            Locations: Mayo Clinic Arizona, Phoenix, Arizona         
        
        
            Conditions: Mesial Temporal Lobe Epilepsy
        
            
        
    
                
                                    Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
                                
            
            
        Recruiting
                            
            
                Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 18 years
            Trial Updated:
                07/23/2025
            
            Locations: Phoenix Children's Hospital, Phoenix, Arizona         
        
        
            Conditions: Partial Epilepsy
        
            
        
    
                
                                    Safety and Efficacy of tPBM for Epileptiform Activity in Autism
                                
            
            
        Recruiting
                            
            
                For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical pract...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 4 years and 12 years
            Trial Updated:
                07/21/2025
            
            Locations: Rossignol Medical Center, Phoenix, Arizona         
        
        
            Conditions: Autism Spectrum Disorder, EEG With Periodic Abnormalities, Epilepsy, Neurodevelopmental Disorders, Neurological Disorder
        
            
        
    
                
                                    A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                05/07/2025
            
            Locations: Barrow Neurological Institute, Phoenix, Arizona  +1 locations         
        
        
            Conditions: Focal Epilepsy
        
            
        
    
                
                                    FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
                                
            
            
        Recruiting
                            
            
                This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                04/03/2025
            
            Locations: Mayo Clinic Arizona Epilepsy Center, Phoenix, Arizona  +1 locations         
        
        
            Conditions: Mesial Temporal Lobe Epilepsy
        
            
        
    
                
                                    Patterns of Neurodevelopmental Disorders
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                04/01/2025
            
            Locations: Rossignol Medical Center, Phoenix, Arizona         
        
        
            Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
        
            
        
    
                
                                    An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
                                
            
            
        Recruiting
                            
            
                An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                03/26/2025
            
            Locations: Praxis Research Site, Phoenix, Arizona         
        
        
            Conditions: Focal Onset Seizure, Primary Generalized Epilepsy
        
            
        
    
                
                                    Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
                                
            
            
        Recruiting
                            
            
                The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/17/2025
            
            Locations: Barrow Neurological Institute, Phoenix, Arizona         
        
        
            Conditions: Epilepsy
        
            
        
    
                
                                    Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
                                
            
            
        Recruiting
                            
            
                The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 18 years
            Trial Updated:
                03/03/2025
            
            Locations: Phoenix Children's Hospital, Phoenix, Arizona         
        
        
            Conditions: Partial Epilepsy
        
            
        
    
                
                                    Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
                                
            
            
        Recruiting
                            
            
                The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate.
This study is currently recruiting.
There is no cost for visits or study-related exams.             
        
        
    Gender:
                ALL
            Ages:
                18 years and below
            Trial Updated:
                12/23/2024
            
            Locations: Southwestern Research and Resource Center, Phoenix, Arizona         
        
        
            Conditions: Autism Spectrum Disorder, Mitochondrial Pathology, Epilepsy, Brain Tumor, Psychiatric Disorder, Mitochondrial Diseases
        
            
        
    